Upstream Bio, Inc.
UPB•NASDAQ•Healthcare•Biotechnology

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOE. Sutherland
Founded2021
IPO DateOctober 11, 2024
Employees52
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websiteupstreambio.com
Phone781 208 2466
Address
890 Winter Street, Suite 200 Waltham, Massachusetts 02451 United States

Corporate Identifiers

CIK0002022626
CUSIP91678A107
ISINUS91678A1079
SIC2834

Leadership Team & Key Executives

Dr. E. Rand Sutherland M.D., M.P.H.
Chief Executive Officer and Director
Michael Paul Gray CPA, MBA
Chief Financial Officer and Chief Operating Officer
Allison C. Ambrose J.D.
Senior Vice President, General Counsel and Secretary
Stacy Price M.S., P.M.P.
Chief Technology Officer
Meggan Buckwell
Director of Corporate Communications and Investor Relations
Lisa Fiering
Senior Vice President of People and Culture
Dr. Adam Houghton M.B.A., Ph.D.
Chief Business Officer
Aaron Deykin M.D.
Chief Medical Officer and Head of Research and Development
Mersedeh Miraliakbari Pharm.D.
Senior Vice President of Regulatory Affairs and Quality
Fang Xie Ph.D.
Vice President and Head of Biometrics